Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Autor: Fabien Zoulim, Kaïdre Bendjama, Carla S. Coffin, Geneviève Inchauspé, Bérangère Bastien, Martin F. Sprinzl, Céline Halluard, Maud Brandely, Vincent Leroy, Ansgar W. Lohse, Heiner Wedemeyer, Mang Ma, François Habersetzer, Claire Fournier, Robert Thimme, Stanislas Pol, Perrine Martin, Karine Lugardon, N. Adda, Benoit Sansas

Publikováno v: Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics, Taylor & Francis, 2020, 16 (2), pp.388-399. ⟨10.1080/21645515.2019.1651141⟩

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afcecc0771d3a1850122a78496465f93
https://hal.science/hal-02441611/document

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Autor: Didier Debieuvre, Radj Gervais, Céline Halluard, A. Madroszyk, Enriqueta Felip, Christian H. Ottensmeier, Christos Chouaid, Andrzej Kazarnowicz, Frederic Forget, György Losonczy, Elisabeth Quoix, Annette Tavernaro, Aleksandra Szczesna, Z. Papai, Bérangère Bastien, J.T. Beck, Gisèle Lacoste, Jean Marc Limacher, Julien Adam, Virginie Westeel, Tania Palanché, Hervé Lena

Publikováno v: The Lancet Oncology. 17:212-223

Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3bb04ca8a5621786fbc8c7aaababfc
https://doi.org/10.1016/s1470-2045(15)00483-0

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results

Autor: Frederic Forget, Virginie Westeel, Bérangère Bastien, Céline Halluard, Radj Gervais, Z. Papai, Gisèle Lacoste, Christos Chouaid, Aleksandra Szczesna, E. Quoix, Andrzej Kazarnowicz, S. Marchand, K. Vanderheyde, Hervé Lena, Christian H. Ottensmeier, György Losonczy, J.T. Beck, Jean-Marc Limacher

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 90:S35

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a487e0e5649d059dcb160a4a8cce4de0
https://doi.org/10.1016/j.ijrobp.2014.08.211